Effects of Icosapent Ethyl on Total Ischemic Events-Reference-Cited by-同舟云学术

Effects of Icosapent Ethyl on Total Ischemic Events

Published:2019-06 Issue:22 Volume:73 Page:2791-2802
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Bhatt Deepak L.,Steg Ph. Gabriel,Miller Michael,Brinton Eliot A.,Jacobson Terry A.,Ketchum Steven B.,Doyle Ralph T.,Juliano Rebecca A.,Jiao Lixia,Granowitz Craig,Tardif Jean-Claude,Gregson John,Pocock Stuart J.,Ballantyne Christie M.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference57 articles.

1. International prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis;Bhatt;JAMA,2006

2. One-year cardiovascular event rates in outpatients with atherothrombosis;Steg;JAMA,2007

3. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis;Bhatt;JAMA,2010

4. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry;Cavender;Circulation,2015

5. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization;Roe;N Engl J Med,2012

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction;Journal of the American College of Cardiology;2024-09

2. The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic Development;JACC: Basic to Translational Science;2024-08

3. Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial;Med;2024-07

4. Impact of empagliflozin on first and recurrent events leading to or prolonging hospitalisation in the EMPA-REG OUTCOME trial;Diabetes Research and Clinical Practice;2024-06

5. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT;European Heart Journal - Cardiovascular Pharmacotherapy;2024-04-27